AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 3 - (NewsRx.com & NewsRx.net) -- The maker of a highly touted experimental Alzheimer vaccine has ended development of the compound after 15 patients suffered serious brain inflammation.
But Elan Corp. said it still is pursuing vigorously a vaccine to slow worsening of Alzheimer and has other candidates that look promising in animal testing.
Still, the March 1, 2002, announcement marked a serious setback.
The Irish drug manufacturer excited researchers in 2000 when it discovered that in mice, the compound code-named AN-1792 could ward off and even reduce brain-clogging plaques that are a hallmark of Alzheimer disease.
Initial safety tests in people showed no adverse effects. But because the vaccine works by inducing the immune system to attack the protein that makes up those plaques, called beta amyloid, some scientists had warned that brain inflammation was a potential serious side effect.
In January 2002, Elan suspended the latest 360-patient ...